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Wnt signalingThe ubiquitin conjugating enzyme Rad6B is overexpressed in breast cancer and induces β-catenin transcrip-
tional activation and stabilization via K63-linked polyubiquitination. Here we identify β-catenin and Rad6B
interacting regions, identify potential Rad6B ubiquitination sites in β-catenin, and characterize their breast
cancer tissue expression. β-catenin and Rad6B colocalize in breast carcinoma and coimmunoprecipitate
from MDA-MB-231 cells. Pull-down assays using GST-β-catenin and His-Rad6B deletion mutants identiﬁed
amino acids 131–181 and 50–116, respectively, as necessary for their interaction. Ubiquitination assays
using β-catenin deletion mutants mapped Rad6B-induced ubiquitination within β-catenin 181–422
encompassing Armadillo repeats 2–7. Lysine to arginine mutations within repeats 5–7 identiﬁed K394 as
the major Rad6B ubiquitination site in vitro and in vivo, and conﬁrmed by Rad6B ubiquitination of a β-
catenin peptide encompassing K394. Ubiquitination of wild type- but not K394R-β-catenin was decreased
by Rad6B silencing. Compared to wild type-, K312R-, K335R-, K345R-, or K354R-β-catenin, K394R mutation
caused ~50% drop in TOP/Flash activity in Wnt-silent MCF-7 cells. Consistent with these data, expression of
Rad6B, itself a β-catenin/TCF transcriptional target, was also reduced in K394R-β-catenin transfected cells.
Steady-state K394R-β-catenin levels are decreased compared to wild type-β-catenin. The decreased expres-
sion is not due to proteasomal degradation as treatment with MG132 failed to rescue its levels. Lymph node-
positive breast carcinomas express higher levels of Rad6 protein and Rad6 activity, and K63-linked
ubiquitinated β-catenin than reduction mammoplasties. These data suggest that K394 is a novel site of β-
catenin ubiquitination that may be important for the stability and activity of β-catenin in breast cancer.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The Rad6 gene, originally identiﬁed in S. cerevisiae, encodes a 17-kDa
ubiquitin conjugating enzyme [1–3] that covalently adds ubiquitin to
selected protein lysine residues. Ubiquitin conjugating activity is essen-
tial for Rad6 function as replacement of the conserved Cys88with Ser or
Ala produces a null phenotype [4,5]. The two human homologues of
yeast Rad6, HHR6A (UBE2A) and HHR6B (UBE2B), referred as Rad6A
and Rad6B, respectively, complement the DNA repair and UVmutagen-
esis defects of S. cerevisiaemutant rad6 [6,7].Wepreviously demonstrated
that Rad6B is overexpressed in breast cancer. Normal human breast tis-
sues weakly express Rad6B, but increased Rad6B expression is observed
in hyperplastic breast tissues with overexpression in inﬁltrating breast
carcinomas [8]. Constitutive Rad6B overexpression in nontransformed
MCF10A human breast epithelial cells induces a transformed phenotypeogy, Wayne State University
nue, Detroit, MI 48201, USA.
ekhar).
rth Road, Ann Arbor, MI 48108,
l rights reserved.as indicated by anchorage independent growth in vitro and formation
of hyperplastic lesions in vivo [8]. These data suggest an oncogenic role
for Rad6B in early breast cancer development. Since constitutive Rad6B
overexpression also induces β-catenin stabilization and transcriptional
activation [9], it is conceivable that Rad6B oncogenic properties are in
part coupled with increased β-catenin activation. The link between
Rad6B and β-catenin is further strengthened by our ﬁnding that Rad6B
is a β-catenin/T-cell factor transcriptional target. Rad6B promoter activa-
tion inMCF10A cells requires ectopic expressionofβ-cateninwhereas it is
constitutively active in metastatic MDA-MB-231 breast cancer cells with
autocrine Wnt signaling [10].
The canonicalWnt signaling pathway regulates several processes in-
cluding early neoplasia. Wnt pathway activation stabilizes β-catenin
and leads to its nuclear translocation and stimulation of β-catenin re-
sponsive target gene expression [11–15]. Aberrant β-catenin activation
is associated with carcinogenesis. Glycogen synthase kinase 3-β (GSK
3β), in complex with axin and adenomatous polyposis coli, regulates
β-catenin via Ser33/Ser37/Thr41 phosphorylation [16,17], which pro-
motes its ubiquitination by β-TrCP/SCF and subsequent proteasomal
degradation [18]. Elevated β-catenin levels are detected in breast can-
cers, suggesting an important role forβ-catenin in breast carcinogenesis
[19–21]. Unlike many other cancers, however, mutations in β-catenin
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suggesting alternative β-catenin stabilization mechanisms. Since
Rad6B is overexpressed in breast cancer cells and stabilizes β-catenin
via K63-linked β-catenin polyubiquitination that is insensitive to 26S
proteasomal degradation, this suggests a novel β-catenin stabilization
mechanism that is mutation independent [9].
Here we show that Rad6, Rad6 ubiquitin conjugating activity, and
polyubiquitinated-β-catenin are co-upregulated in clinical breast carci-
nomas. Using coimmunoprecipitation and pull-down assays, we show
that Rad6B andβ-catenin proteins physically interactwithin theﬁrst ar-
madillo repeat (ARM1) segment of β-catenin and amino acids 50–116
of Rad6B. By site-directed mutagenesis and in vivo and in vitro
ubiquitination assays, we identiﬁed β-catenin K394 as a major site of
Rad6B-induced β-catenin ubiquitination. β-catenin K394R exhibits de-
creased β-catenin-mediated TOP/Flash activity, and expression of
Rad6B, itself a β-catenin/TCF transcriptional target, is reduced in
K394R-β-catenin transfected MCF-7 cells. Steady-state K394R-β-
catenin levels are decreased compared to wild type β-catenin and β-
catenin containing K to R mutations at amino acids 312, 335, 345 or
354. Treatment with the proteasomal inhibitor MG132 failed to rescue
its levels, indicating decreased expression is not due to proteasomal
degradation. These data reveal K394 as a novel site of β-catenin
ubiquitination and a potentially novel charge button that may be im-
portant for maintaining β-catenin structure and stability.
2. Materials and methods
2.1. Cell culture
MCF-7 breast cancer cells were maintained in Dulbecco's modiﬁed
Eagle/F-12 medium (DMEM/F12) supplemented with 5% fetal calf
serum and 10 μg/ml insulin [23]. MCF10A-Neo and MCF10A-Rad6B [8]
cells were maintained in DMEM/F12 supplemented with 5% horse
serum, 20 ng/ml Epidermal Growth Factor, 10 μg/ml insulin, 0.5 μg/ml
hydrocortisone and 0.1 μg/ml cholera toxin. MDA-MB-231, MDA-MB-
231-nontarget shRNA, MDA-MB-231-Rad6BshRNA [9], MDA-MB-231-
ΔLRP6 [24,25], WS-15, WS-15-nontarget shRNA, WS-15-Rad6BshRNA
[9] and COS7 (ATCC) cells were maintained in DMEM/F12 sup-
plemented with 5% fetal bovine serum.
2.2. Antibodies
β-catenin and β-actin monoclonal antibodies were from Sigma
Chemical Company. Glutathione S-transferase (GST), His tag, c-Myc,
HA tag, and ubiquitin (P4D1) monoclonal antibodies were from Santa
Cruz Biotechnology. Antibody reactive to K63-linked ubiquitin conju-
gated chains was from Biomol International. Cyclin D1 and cytokeratin
18 monoclonal antibodies were from Dako Corporation. Rad6 antibody
was generated and characterized in our laboratory [8]. MassSpec analy-
sis of tryptic peptides of Rad6 proteins immunoprecipitated from
MCF10A andMDA-MB-231 cells identiﬁed only parent ionmasses iden-
tical to the predicted Rad6B, but not Rad6A, tryptic peptides, conﬁrming
identity of immunoreactive Rad6B bands (unpublished data). However,
since the antibody is not Rad6B selective and sequences of Rad6 pro-
tein(s) detected by immunoblotting of every breast tissue used have
not been veriﬁed, the endogenous Rad6 protein detected in immuno-
blots is referred to as Rad6 rather than Rad6A or Rad6B. Myc tag anti-
body was a generous gift from Dr. Vitaly Balan (Wayne State
University, Detroit, Michigan).
2.3. Vectors and recombinant protein expression
Human Rad6B 1–152 (wild type), rad6B 50–152 and rad6B
116–152 mutants were ampliﬁed by PCR from pCMV-wild type
Rad6B[8] using forward primers 5′-caccatgtcgaccccggcccgg-3′
(for Rad6B 1–152), 5′-caccatggatggtacttttaaactagta-3′ (for rad6B50–152), 5′-caccatgccgaatccaaacagtccagcc-3′ (for rad6B 116–152), and
the reverse primer 5′-tgaatcattccagctttgttcaac-3′. Rad6B and rad6B
mutants were subcloned into pET101 to encode Rad6B tagged to a
C-terminal (His)6. Catalytically inert Rad6B C88A was generated by
site-directed mutagenesis using wild type Rad6B pET vector. The fol-
lowing β-catenin constructs subcloned into pGEX-2T were used:
full-length 1–781, β-catenin 131–422, β-catenin 181–422, K312R-,
K335R-, K345R-, K354R-, and K394R-β-catenin. β-catenin 131–422
and β-catenin 181–422 plasmids were generous gifts from Dr. L.A.
Pinna (University of Padova, Italy). Mutant β-catenin proteins in
which lysine residues 312, 335, 345, 354, or 394 were substituted
with arginine were generated by site-directed mutagenesis of GST-
tagged wild type β-catenin or pCI-neo-myc-tagged β-catenin tem-
plate. Myc-tagged β-catenin 1–781, 1–699, 131–699 and 555–781
subcloned into pCI-neo were generous gifts from Dr. Yutaka Hata
(Tokyo Medical and Dental University, Japan). Rad6B and β-catenin
sequences and β-catenin lysine to arginine substitutions were con-
ﬁrmed by DNA sequencing.
2.4. Expression
His-tagged wild type and mutant Rad6B, and GST-tagged wild type
and mutant β-catenin plasmids were expressed in Escherichia coli
BL21 (DE3). His-tagged Rad6B proteins bound to Ni+2-nitrilotriacetic
acid-agarose columns were eluted with 1 M imidazole following se-
quential washes with 5 and 60 mM imidazole. GST-β-catenin fusion
proteins bound to glutathione-agarose beads were eluted with 20 mM
glutathione. The purity of the isolated proteins was veriﬁed by silver
staining.
2.5. Clinical samples
Nonidentiﬁable breast tissue samples (reduction mammoplasties,
lymph node (LN)-negative, LN-positive, and metastatic lymph nodes)
ﬂash-frozen in liquid nitrogen were acquired by written consent of
the Institutional Biorepository Core after review and approval by the
Wayne State University Human Investigation Committee. Only surgi-
cal excisions that remained after diagnostic conﬁrmation were used
for experiments.
2.6. Immunoblotting and immunoprecipitation
Frozen samples ground to a ﬁne powder were suspended in cold
lysis buffer (25 mM HEPES [pH 7.5], 25 mM NaCl, 0.1% Nonidet P-40,
10% glycerol) containing protease inhibitor (Roche) and phosphatase
inhibitor (1 mM sodium orthovanadate, 20 mM NaF, 10 mM sodium
pyrophosphate and 10 mM β-glycerol phosphate) cocktails and ho-
mogenized. Homogenates were passed through a 19 ga needle until
no longer viscous. Lysates were centrifuged at 18,000×g at 4 °C for
30 min, and the resulting cytosolic extracts containing 100 μg total pro-
tein were separated by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE), and analyzed by immunoblotting with Rad6
[8], β-catenin [9], β-actin and cytokeratin 18 [26] antibodies. For β-
catenin ubiquitination status determination, precleared cytosols
were incubated with β-catenin antibody (1 μg) and Protein A/G
Sepharose. Bound proteins were resolved by SDS-PAGE and immu-
noblotted with ubiquitin or K63-linked ubiquitin chain antibody.
Rad6 and ubiquitinated β-catenin levels were expressed relative to
nascent β-catenin, and nascent β-catenin expressed relative to
cytokeratin-18. For characterizing in vivo Rad6/β-catenin interac-
tions, Protein A/G Sepharose precleared cytosols were incubated
with Protein A/G Sepharose and anti-β-catenin (1 μg) or anti-Rad6
(1 μg) or the corresponding normal mouse or rabbit IgG. Co-
precipitated β-catenin or Rad6 was then determined by immuno-
blotting. Cytosols prepared from MCF10A-Neo, MCF10A-Rad6B,
MDA-MB-231-nontarget shRNA, MDA-MB-231-Rad6BshRNA, MDA-
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cells were analyzed by immunoblotting with Rad6 and β-catenin an-
tibodies. Semi-quantitation of bands was performed by scanning
densitometry and NIH ImageJ 1.45s software.
2.7. Rad6B ubiquitin conjugating activity assay
Histone H2A ubiquitination was assessed in extracts (100 μg) of re-
duction mammoplasties and tumor tissue as described above. Samples
were incubated at room temperature for 1 h with histone H2A (2.5 μg;
Roche Biotech), ubiquitin activating enzyme E1 (50 μg/ml, BioMol),
ubiquitin (1.25 mg/ml; Roche), 2 mMMgCl2, 4 mM ATP and energy re-
generation system (Boston Biochem) in reaction buffer (50 mM Tris–
HCl [pH 7.5]) [9]. To verify the involvement of endogenous Rad6B in his-
tone ubiquitination, some reactions were performed in the presence of
catalytically inert rad6B (85 μg/mL; Boston Biochem), without histone
H2A, or with Rad6B immunodepleted extracts. For immunodepletion,
tissue extracts were incubated with anti-Rad6 or normal rabbit IgG
(1.0 μg) andProtein A/G Sepharose overnight. After pelleting complexed
proteins, depleted supernatants were used in ubiquitination assays. For
a positive control, tissue extracts were substitutedwithwild type Rad6B
(85 μg/ml; Boston Biochem). Reaction products were separated by SDS-
PAGE and analyzed by silver staining or immunoblotting with ubiquitin
and Rad6 antibodies.
2.8. Ubiquitination site mapping
Cytosolic extracts of COS7 cells expressing myc-tagged β-catenin
1–781, β-catenin 1–699, β-catenin 131–699 or β-catenin 551–781
were subjected to in vitro ubiquitination assays with or without re-
combinant Rad6B as described above. Reaction products were sepa-
rated by SDS-PAGE and immunoblotted with myc tag antibody.
Rad6B-induced in vitro ubiquitination of puriﬁed GST-tagged-β-
catenin 131–422, β-catenin 181–422, or β-catenin containing muta-
tions at 312, 335, 345, 354 or 394 was assessed as previously de-
scribed [9]. Reactions were subjected to SDS-PAGE and immunoblotted
with ubiquitin or GST antibody. The corresponding amounts of β-
catenin proteins used in ubiquitination assays were determined by
Coomassie staining. Ubiquitination of β-catenin carrying K312R, K345R,
K354R, or K394R mutations was determined in MCF-7, or nontarget or
Rad6BshRNA transfected MDA-MB-231 cells cotransfected with myc-
tagged wild type or mutant β-catenin and pMT123 (HA-tagged ubiquitin
expression vector [27]). Lysates were immunoprecipitated with myc tag
antibody before HA tag antibody immunoblotting. To further verify the
identiﬁed Rad6B induced β-catenin ubiquitination site, in vitro
ubiquitination assays were performed with a synthetic 29-amino acid
β-catenin peptide NLSDAATKQEGMEGLLGTLVQLLGSDDIN encompassing
K394. Reactions were performed with methylated ubiquitin [9] and wild
type or catalytically inert Rad6B. Methylated ubiquitin was used instead
of ubiquitin as it limits addition of a single ubiquitin molecule and pre-
vents ubiquitin dimerization resulting from ubiquitin self-conjugation,
thus enabling cleaner visualization of the ubiquitinated peptide on silver
stained gels.
2.9. In vitro pull-down assays
To map β-catenin regions interacting with Rad6B, puriﬁed His-
tagged Rad6B 1–152 protein was incubated with control or GST-
β-catenin (1–781, 131–422, or 181–422) proteins bound to gluta-
thione (GSH)-Sepharose for 4 h at 4 °C in binding buffer (100 mM
sodium phosphate [pH 7.2], 150 mM NaCl, 1 mM MgCl2, 0.5% NP-
40, 1 mM dithiothreitol, and protease inhibitor cocktail). The
beads were washed with binding buffer followed by washes in
buffer containing 500 mM NaCl. The bound proteins were resolved
by SDS-PAGE and analyzed by immunoblotting with His tag or GST
antibodies. To map Rad6B interaction sites on β-catenin, His-tagged Rad6B 1–152, rad6B 50–152, rad6B 116–152 or GST-β-
catenin 1-781 proteins were expressed in Escherichia coli BL-21.
Bacterial lysates containing equivalent amounts of Rad6B 1–152,
rad6B 50–152 or rad6B 116–152, and GST-β-catenin 1–781 were
loaded on Ni+2-nitrilotriacetic acid-agarose beads or GSH-
Sepharose beads and processed as above. Interactions between
His-tagged wild type or catalytically inactive C88A rad6B 1–152
and GST-β-catenin 1–781 and their elution proﬁles were deter-
mined by processing bacterial lysates containing Rad6B and β-
catenin on Ni+2 nitrilotriacetic acid agarose or GSH-Sepharose col-
umns. Ni+2 columns were washed with binding buffer, and
sequentially with buffer containing 5 mM, 60 mM and 1 M imidaz-
ole. GSH-Sepharose columns were washed with binding buffer
containing 500 mM NaCl and eluted with 20 mM glutathione. Col-
umn fractions were analyzed by immunoblotting with His tag or
GST antibodies.2.10. Luciferase assays and gene expression analysis
Transcriptional activities of K312R-, K335R-, K345R-, K354R-, or
K394R-β-catenin mutants relative to wild type β-catenin were assayed
by cotransfecting MCF-7 cells with myc-tagged β-catenin plasmid
(1 μg), pTOP/FLASH or pFOP/FLASH (0.5 μg; Upstate Biotechnology),
p300 (0.25 μg), and pRLTK (100 ng; Promega) vectors as previously de-
scribed [9]. P300 was included in transfections since it enhances tran-
scriptional activity of the expressed β-catenin [8]. In some cases,
1–4 μg of wild type- or K394R-β-catenin were transfected. Cyclin D1
promoter-driven luciferase or c-Myc promoter-driven luciferase re-
porters were substituted for pTOP/FLASH in some assays. Luciferase ac-
tivity was measured ~48 h post-transfection with Promega Dual
Luciferase assay system, and ﬁreﬂy luciferase activity was normalized
against Renilla luciferase. The background luciferase activities from
corresponding pFOP/FLASH transfections were subtracted. Duplicate
disheswere assayed for each transfection, and three independent trans-
fection assays were performed. Lysates from transfection assays were
also analyzed by immunoblotting for Rad6, cyclin D1 [28], c-Myc [29],
and myc-tagged β-catenin, and normalized against β-actin.2.11. Semi-quantitative RT-PCR
Total RNA (1. 0 μg) isolated from MCF-7 cells transfected with
myc-tagged wild type or mutant β-catenin (1.0 μg) and p300
(0.25 μg) was reverse-transcribed with Superscript II (Invitrogen,
Carlsbad, CA). Rad6B ampliﬁcation was performed with +17/+33
and +114/+97 [GenBank: NM_003337] forward and reverse
primers, respectively. GAPDH expression was monitored by ampliﬁ-
cations with forward (+186/+206) and reverse (+320/+302)
[GenBank: XM_006959] primers. PCR reaction conditions that yielded
linear product ampliﬁcation were used: 5 min 95 °C, 1 min 55 °C,
2 min 65 °C for 21 cycles.2.12. Immunohistochemical and immunoﬂuorescence staining
Deparafﬁnized 5 μm sections from normal and inﬁltrating ductal
breast carcinomas were permeabilized and incubated with Rad6 or
β-catenin antibodies. After primary antibodies, slides were incubated
with FITC- and Texas Red-conjugated secondary antibodies, or with
appropriate biotinylated anti-rabbit or mouse IgG and HRP-
conjugated streptavidin, and nuclei were counterstained with hema-
toxylin. Slides were stained in the absence of primary antibody or
with isotype matched nonimmune IgG to assess nonspeciﬁc reac-
tions. Images were collected on an Olympus BX60 microscope
equipped with a Sony high resolution/sensitivity CCD video camera.
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Kruskal–Wallis tests were used to compare relative levels of
Rad6B, native β-catenin and high MW β-catenin from reduction
mammoplasties or benign tissues (n=9), tumor samples from LN-
negative (n=16) or LN-positive (n=11) breast cancer patients,
and lymph node samples from women with metastatic disease
(n=10). Signiﬁcance of differences in transcriptional activities of β-
catenin mutants was determined by Student's t test. Statistical calcu-
lations were conducted using GraphPad Prism 4 software.
3. Results
3.1. Rad6B and β-catenin physically interact
Cytoplasmic/nuclear β-catenin staining with or without loss of cell
membrane associated β-catenin has been associated with poor prog-
nosis of breast cancer [30]. A positive association between Rad6 and
β-catenin immunostaining patterns is observed in ~72% of the breast
carcinomas analyzed [10]. Immunohistochemical analysis of Rad6
and β-catenin in representative clinical samples show different cellu-
lar distributions (Fig. 1A). Whereas β-catenin is associated with cell
membranes in normal breast tissues (reduction mammoplasties,
Fig. 1Aa′), it is either present on cell membranes and cytoplasm/nuclei
(Fig. 1Ab′) or in the cytoplasm/nuclei with loss of membrane
staining (Fig. 1Ac′) in breast cancer. Rad6 also showed changes in
cellular distribution. Rad6 staining isweak in reductionmammoplasties
(Fig. 1Aa), but is detected in the cytoplasm (Fig. 1Ab) or in both cyto-
plasm and nuclei (Fig. 1Ac) of clinical breast carcinomas. Immunoﬂuo-
rescence staining showed Rad6 and β-catenin colocalization in
inﬁltrating ductal carcinoma (Fig. 1Bb″) but not in reduction
mammoplasty (Fig. 1Ba″). In WS-15 human breast cancer cells, Rad6
and β-catenin also colocalized (Fig. 1Bc–c″), corroborating clinical
breast cancer immunostaining (Fig. 1A). Consistent with the immuno-
ﬂuorescence data, immunoprecipitation with β-catenin antibody
(epitope 680–781) pulled down Rad6 along with nascent and high
MW β-catenin fromMDA-MB-231 cytosols. Likewise, Rad6 antibody ef-
ﬁciently pulled down Rad6 alongwith nascent and highMW β-catenin,
whereas normal IgGs failed to immunoprecipitate Rad6 or β-catenin
(Fig. 1C).
3.2. Rad6B interacts with the ﬁrst armadillo repeat (ARM1)-containing
segment of β-catenin
To map Rad6B/β-catenin interactions, pull-down assays were per-
formed. As shown in Fig. 1D (bottom panel), wild type Rad6B (lane 1)
bound to GST-β-catenin 1–781 (lane 9) and GST-β-catenin 131–422
(lane 10) but not to GST-β-catenin 181–422 (lane 11). Binding was
β-catenin speciﬁc, as Rad6B did not bind to control GSH-Sepharose
(lane 5, Fig. 1D, bottom panel). Rad6B bound similarly to GST-β-
catenin 1–781 and GST-β-catenin 131–422 (compare lanes 9 and
10, bottom panel) but did not bind to GST-β-catenin 181–422 (com-
pare lanes 9 and 10 with 11), suggesting that Rad6B/β-catenin inter-
action requires the β-catenin 131–181 segment encompassing ARM1.
Incubation with Rad6B did not affect GST-β-catenin protein binding
to GSH-Sepharose since similar amounts of β-catenin proteins
bound to beads in the absence (Fig. 1D upper panel, lanes 6–8,
input) or presence (Fig. 1D upper panel, lanes 9–11) of Rad6B.
Pull-down assays of the Rad6B/β-catenin mixture on Ni+2-aga-
rose (Fig. 1E) conﬁrmed the Rad6B/β-catenin interaction data from
GSH-Sepharose binding assays in Fig. 1D. β-catenin associated with
Rad6B 1–152 and rad6B 50–152, but not rad6B 116–152 (Fig. 1E
upper panel, lanes 7–9). β-catenin GSH-Sepharose pull-down assays
further conﬁrmed the inability of rad6B 116–152 to bind β-catenin
(Fig. 1E upper panel, lane 6) whereas Rad6B 1–152 and rad6B
50–152 associated similarly with β-catenin 1–781 (Fig. 1E upperpanel, lanes 4 and 5). These data suggest that Rad6B amino acids
50–116 interact with β-catenin amino acids 131–181 (Fig. 1D and E,
right panels). These ﬁndings imply that the Rad6B and β-catenin
colocalization observed in Fig. 1B and the positive association be-
tween Rad6B and β-catenin staining in clinical breast cancer
(Fig. 1A; [10]) potentially reﬂect endogenous Rad6B/β-catenin
interactions.
3.3. Interaction with β-catenin is not affected by mutation in the Rad6B
catalytic site
Since β-catenin is a Rad6B-mediated ubiquitination substrate, we
tested whether this interaction requires the Rad6B catalytic site. Both
wild type (Fig. 2A, left panel) and mutant (Fig. 2A, right panel) Rad6B
bound very strongly to Ni+2 agarose as their elution required 1 M im-
idazole. However, when complexed with β-catenin, some Rad6B was
eluted by 60 mM imidazole (Fig. 2B, left and right panels), whereas
Rad6B uncomplexed to β-catenin was eluted by 1 M imidazole
(Fig. 2B, left and right panels). These data suggest that complex for-
mation with β-catenin altered His-tagged Rad6B afﬁnity for Ni+2
agarose. The similar elution proﬁles for β-catenin complexed with
wild type (Fig. 2B and C, left panels) and mutant (Fig. 2B and C,
right panels) Rad6B suggest that β-catenin–Rad6B interaction is
unaffected by the Rad6B catalytic site mutation. Rad6B and GST-β-
catenin coelution from GSH beads by glutathione further corroborates
Rad6B/β-catenin interaction data (Fig. 2D).
3.4. Lysine 394 of β-catenin is a major site of Rad6B mediated
ubiquitination
To map β-catenin lysine(s) that are ubiquitinated by Rad6B, in
vitro ubiquitination assays were performed with recombinant
Rad6B and extracts of COS7 cells transfected with various myc-
tagged β-catenin deletion mutants. Rad6B ubiquitinated β-catenin
1–699 (Fig. 3A, arrow in b, b′) and β-catenin 131–699 (Fig. 3A,
arrow in b′) but not β-catenin 555–781 (Fig. 3A, b and b′). The
corresponding control reactions performed without recombinant
Rad6B showed no β-catenin ubiquitination (Fig. 3A, panel a). GST-
β-catenin 181–422 and GST-β-catenin 131–422 proteins were
ubiquitinated by recombinant Rad6B in vitro (indicated by bracket
in Fig. 3A, panel c). Taking together, these data suggest that lysine res-
idues located between amino acids 181–422 of β-catenin are the
major targets of Rad6B-induced ubiquitination.
The β-catenin 181–422 segment encompasses ARMs 2–7 and con-
tains 10 lysine residues. ARMs 5–9 are implicated in interactions with
TCF-4 and other cellular partners and regulate β-catenin transcrip-
tional activity ([31] and references within). We have previously
shown that ectopic Rad6B induces polyubiquitinated-β-catenin levels
and β-catenin transcriptional activity in MCF10A cells. Conversely,
Rad6B silencing in MDA-MB-231 and WS-15 breast cancer cells
with autocrine Wnt signaling decreases polyubiquitinated-β-catenin
levels and transcriptional activity [9]. Based on these data, we rea-
soned that the lysine(s) ubiquitinated by Rad6B and modulating β-
catenin transcriptional activity may include the ﬁve lysines (312,
335, 345, 354, 394) located in ARMs 5–7 (Fig. 3B). GST-wild type-β-
catenin and mutants GST-β-catenin K312R, K345R, and K354R were
efﬁciently ubiquitinated by Rad6B in vitro as indicated by the pres-
ence of two anti-ubiquitin reactive bands (Fig. 3C, arrows). Relative
to corresponding single mutants, K312/345/354R-β-catenin
ubiquitination was reduced but not abolished, conﬁrming these
amino acids are not essential for Rad6B-induced ubiquitination
(Fig. 3C). K335R-β-catenin was weakly ubiquitinated, while the
K394R mutation abrogated ubiquitination (Fig. 3C). The reduced
ubiquitination efﬁcacy observed with K312/345/354R-β-catenin as
compared to single mutants probably resulted from conformational
changes that inﬂuenced accessibility of K394 to Rad6B. Wild type
Fig. 1. Rad6B and β-catenin exhibit direct interactions. (A) Immunohistochemical analysis of Rad6 (a, b, c) and β-catenin (a′, b′, c′) in reduction mammoplasty (a, a′) and clinical
breast carcinomas (b, b′, c, c′). (B) Immunoﬂuorescence localization of Rad6 (a, b and c) and β-catenin (a′, b′ and c′) in reduction mammoplasty (a–a″), inﬁltrating ductal carcinoma
(b–b″), and WS-15 breast cancer cells (c–c″). Magniﬁcation ×20 (a–a″ and b–b″) and ×100 (c–c″). (C) Co-immunoprecipitation analysis. Lane 1, 1/5th of MDA-MB-231 cytosol in-
puts. (D) Mapping β-catenin interacting regions. Pull-down assays from GSH-beads with His-tagged wild type Rad6B 1–152 (lanes 9–11) and GST-tagged β-catenin 1–781 (lane 9),
β-catenin 131–422 (lane 10) or β-catenin 181–422 (lane 11) proteins. Lanes 1–4, inputs of His-Rad6B, GST-β-catenin 1–781, GST-β-catenin 131–422, and GST-β-catenin 181–422,
respectively. Lanes 5–8, control GST, GST-β-catenin 1–781, GST-β-catenin 131–422, and GST-β-catenin 181–422, respectively. Blots were probed with GST (upper) and His (bot-
tom) antibodies. (E) Mapping Rad6B interaction sites. Pull-down assays were performed with His-tagged Rad6B 1–152 (lanes 4 and 7), Rad6B 50–152 (lanes 5 and 8) or Rad6B
116–152 (lanes 6 and 9) and GST-β-catenin 1–781 (lanes 4–9) on GSH-beads (lanes 4–6) or Ni+2-beads (lanes 7–9) beads. Lanes 1–3, inputs of Rad6B 1–152, Rad6B 50–152,
Rad6B 116–152, and GST-β-catenin 1–781. Blots were probed with His (upper) and GST (bottom) tag antibodies. Rad6B/β-catenin interaction regions are shown schematically
in the right panels of D and E.
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conﬁrming reaction speciﬁcity (Fig. 3C). In vitro ubiquitination assays
using a 29 amino acid β-catenin synthetic peptide containing K394
were performed to verify these results. As shown in Fig. 3D, β-catenin
peptide ubiquitination occurs in the presence of wild type Rad6B but
not catalytically inactivemutant rad6B. Rad6B ubiquitin conjugating ac-
tivity was conﬁrmed by detection of ubiquitin-conjugated Rad6B in re-
actions containing wild type but not catalytically inactive Rad6B
(Fig. 3D).
Next we characterized in vivo ubiquitination of the β-catenin
K312R, K335R, K345R, K354R and K394R mutants in MCF-7 cells.
Compared to wild type-β-catenin, mutants showed decreased
ubiquitination, with β-catenin K394R showing the largest decrease
(Fig. 3E and right panel). Variations in ubiquitination in vivo can result
from variant expressions of transfected ubiquitin or mutant β-catenin,
and/or from reduced efﬁciencies of ubiquitination of the mutant pro-
teins. To verify whether in vivo ubiquitination of K394R-β-catenin is af-
fected by Rad6B silencing, MDA-MB-231 cells were transfected withnontarget shRNA or Rad6BshRNA, and myc-tagged wild type, K354R-
or K394R-β-catenin and ubiquitin expression plasmids. Wild type and
K354R-β-catenin were efﬁciently ubiquitinated, and ubiquitination
was inhibited by Rad6BshRNA (Fig. 4A and C). As in MCF-7 cells
(Fig. 3E), K394R-β-catenin ubiquitination was compromised in MDA-
MB-231 cells and was minimally affected by Rad6B silencing (Fig. 4A,
B and C). These data conﬁrm that K394 is a physiologically relevant
site of Rad6B-mediated β-catenin ubiquitination. However, since
K394R-β-catenin ubiquitination, albeit low compared to wild type β-
catenin, is observed, this suggests additional Rad6B-independent
ubiquitinating events.
3.5. Lysine 394 mutation decreases β-catenin transcriptional activity
To characterize the role of lysines 312, 335, 345, 354 or 394 in β-
catenin transcriptional activity, the myc-tagged mutants were tested
for their ability to support reporter transactivation and expression
of transcriptional targets Rad6B, cyclin D1 and c-Myc. Wild type β-
Fig. 2. Physical interaction between Rad6B and β-catenin is not affected by mutation (Cys88 to Ala) in the ubiquitin conjugation catalytic site. (A, B) Elution proﬁles of His-tagged
wild type Rad6B or catalytically mutant rad6B from Ni+2 beads in the absence (A) and presence (B) of GST-wild type β-catenin, and detected with His tag or GST antibodies.
(C) Graphic representation of Rad6B and β-catenin elution proﬁles in A and B. (D) Elution proﬁles of wild type Rad6B and GST-wild type β-catenin from GSH-Sepharose.
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to empty vector-transfected cells (Fig. 5A). Compared to wild type,
the increase in TOP/Flash activity was reduced by 10–23% in cells
transfected with K312R-, K335R-, K354R- or K345R-β-catenin, but
this difference was not signiﬁcant. TOP activation by K394R-β-
catenin, however, was reduced by ~50% (Pb0.01) compared to wild
type β-catenin (Fig. 5A). To verify the decreased transcriptional activ-
ity of K394R-β-catenin, TOP/Flash assays were performed with vari-
ous amounts of wild type and K394R-β-catenin. Whereas 1, 2 and
4 μg of wild type β-catenin robustly supported TOP/Flash reporter
transactivation, TOP/Flash activity was not signiﬁcantly enhanced by
increasing amounts of K394R-β-catenin (Fig. 5B). Simultaneous anal-
ysis of lysates for expression of myc-tagged wild type and K394R-β-
catenin indicated that the drop in reporter activation by K394-β-
catenin is not rescued commensurately by increasing levels of the
mutant (Fig. 5B, lower panel). Expression of Rad6B, itself a transcrip-
tional target of β-catenin/TCF, was also not enhanced by K394R-β-
catenin, and resembled the TOP/Flash reporter data (Fig. 5B and
lower panel).
To verify the reporter transactivation data in Fig. 5A, expression
of myc-tagged β-catenin and β-catenin transcriptional targets
Rad6B, cyclin D1, and c-Myc were analyzed in MCF-7 cells. Rad6
protein was induced by wild type, K312R-, K335R-, K345R-, or
K354R-β-catenin (Fig. 5D). As in Fig. 5B (lower panel), induction
of Rad6 was lower in K394R-β-catenin transfected cells (Fig. 5D).
RT-PCR analysis conﬁrmed that the decrease in Rad6B protein in
K394R-β-catenin transfected cells is due to reduced Rad6B tran-
scription (Fig. 5C). Analysis of β-catenin transcriptional target c-
Myc regulation as indicated by c-Myc promoter-driven luciferase
expression showed an ~25% decrease in K394R-β-catenin trans-
fected cells compared to wild type β-catenin transfected cells(data not shown). c-Myc protein levels were also decreased, al-
though not as dramatically as Rad6B, in K394R-β-catenin trans-
fected cells (Fig. 5D). Cyclin D1 promoter activity (measured by
cyclin D1 promoter-luciferase assays) was unaffected by the
K394R mutation (data not shown), and cyclin D1 protein levels
were minimally affected (Fig. 5D). The steady state levels of
K394R-β-catenin were reduced compared to other mutants or
wild type β-catenin (Fig. 5D), and addition of the 26S proteasome
inhibitor MG132 did not rescue K394R-β-catenin levels (Fig. 5E).
These data suggest that K394 may play an important role in
maintaining the steady-state levels of β-catenin and its transcrip-
tional activity.
3.6. Rad6 and ubiquitin-modiﬁed β-catenin levels are co-upregulated in
breast carcinomas
The relationship between the presence of high MW β-catenin and
Rad6B seen in human breast cancer cells overexpressing Rad6B
(MCF10A-Rad6B, MDA-MB-231,WS-15) or silenced for Rad6B gene ex-
pression (MDA-MB-231-Rad6BshRNA, WS-15-Rad6BshRNA) is shown
in Fig. 6A. To determine whether a positive relationship between Rad6
levels and β-catenin ubiquitination also exists in clinical breast cancer,
Rad6 and β-catenin protein levels were analyzed in cytosols from re-
duction mammoplasties (RM) or nontumor tissues, lymph node (LN)-
negative, LN-positive, and metastatic lymph nodes. Representative
blots and graphic summarization of Rad6 and β-catenin proﬁles are
shown in Fig. 6B, C and D. Rad6 and high MW β-catenin (>90 kDa)
levels were normalized against nascent β-catenin since it was present
in all samples regardless of tumor grade. Steady-state levels of nascent
β-catenin were normalized against cytokeratin-18, an epithelial-cell
speciﬁc marker, rather than β-actin, since β-actin is not epithelial cell-
Fig. 3. Lysine 394 of β-catenin is a major Rad6B ubiquitination site. (A) Cytosols from COS7 cells transfected with indicated myc-tagged β-catenin (a, b, b′) or puriﬁed GST-β catenin
(181–422 and 131–422; panel c) were subjected to in vitro ubiquitination assays with recombinant Rad6B (panels b, b′, and c). Panel a, control reactions performed without Rad6B.
Panel b′ is a longer exposure of b. Anti-myc and GST-tag reactive ubiquitinated β-catenin are indicated by arrows in b and b′, and bracket in c, respectively. (B) Schematic repre-
sentation of lysines in ARMs 5–7. (C) Rad6B ubiquitination of puriﬁed GST-wild type (Wt) or K to R substituted β-catenin proteins. Last lane, wild type β-catenin reaction lacking
Rad6B. Immunoblots were probed with ubiquitin antibody. Arrows indicate the positions of the ubiquitinated doublet bands of β-catenin. Left blot, GST-β-catenin proteins without
reaction and detected by GST tag antibody. Bottom panel, Coomassie staining of GST-β-catenin proteins used in the reactions. (D) In vitro ubiquitination of K394 containing β-
catenin peptide performed in the presence of wild type (Wt) or catalytically inert (mut) Rad6B andmethylated ubiquitin (me-Ub). Lanes *, ** indicate me-Ub and β-catenin peptide,
respectively. Reaction products were detected by silver staining. (E) In vivo ubiquitination of myc-tagged wild type or mutant β-catenin in MCF-7 cells. Right panel, graphic rep-
resentation of wild type and mutant β-catenin ubiquitination.
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stromal cells. Expression of cytokeratin-18 itself is variable in clinical
samples, and loss of cytokeratin-18 has been correlatedwith breast can-
cer progression [32]. Signiﬁcantly higher Rad6 levels were observed in
LN-positive breast carcinomas (P=0.01) and metastatic lymph nodes
(P=0.003) compared to RMs or benign breast tissues (Fig. 6B, C, and
D). Nascent β-catenin levels were not signiﬁcantly different in non-
tumor and tumor tissues. β-catenin high MW forms were readily
detected with β-catenin antibody and in Westerns of β-catenin anti-
body immunoprecipitates with ubiquitin or K63-linked ubiquitin
chain antibody. β-catenin high MW forms were signiﬁcantly higher in
LN-positive breast cancer (P=0.002) and metastatic lymph nodes
(Pb0.001) as compared to RMs (Fig. 6C and D).
3.7. Rad6 ubiquitin conjugation activity is upregulated in invasive breast
carcinomas
To determinewhether elevated Rad6 expression levels in breast car-
cinomas [8] translate into commensurate increases in ubiquitinatingactivity, histone H2A ubiquitination assays were performed in extracts
fromnormal (RM), LN-negative and LN-positive breast carcinomas. His-
tones H2A and H2B are ubiquitinated by Rad6 [33,34]. Whereas mon-
oubiquitinated histone H2A was undetectable in reactions involving
RM (Fig. 6E), a conspicuous band with similar mobility to a band pre-
sent in parallel recombinant wild type Rad6B reactions (Fig. 6E and F,
arrow) was observed in LN-positive tumor extract reactions (Fig. 6E
and F, LN+ lanes). Addition of catalytically inert rad6B in LN+ tumor
reactions markedly inhibited histone H2A ubiquitination as compared
to corresponding reactions not supplemented with mutant rad6B
(Fig. 6E, compare *LN+ lanes with or without mutant rad6B). The
ubiquitinated band was not detected in Rad6-immunodepleted tumor
reactions (Fig. 6F, compare *LN+ reactions performed after Rad6 deple-
tion vs. normal IgG control). Silver stains and ubiquitin antibody immu-
noblots of H2A ubiquitination reactions performed with or without
recombinant Rad6B or histone H2A authenticate Rad6B ability to ubiq-
uitinate H2A (Fig. 6G). These data conﬁrm that the ubiquitinated band
formed with LN+ tumor extracts indeed represents H2A mono-
ubiquitination mediated by endogenous Rad6.
Fig. 4. K394R-β-catenin ubiquitination is unaffected by Rad6B silencing. MDA-MB-231 cells were transfected with nontarget (NT) or Rad6B (R6B) shRNA and myc-tagged wild type
(WT), K354R- or K394R-β-catenin and HA-ubiquitin. (A) Western blot analysis. (B and C) Graphic representation of Rad6 and ubiquitinated β-catenin, respectively. * and ns indi-
cate signiﬁcant (Pb0.001) and no signiﬁcant difference, respectively.
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The data presented here provide novel evidence for a Rad6B role
in β-catenin stabilization and activation in breast cancer.
Coimmunoprecipitation, immunolocalization, and pull-down assays
showed that Rad6B and β-catenin physically interact, and the inter-
acting regions reside between amino acid residues 50–116 of Rad6B
and 131–181 of β-catenin encompassing ARM1. The amino acid
131–181 region is implicated in recognition and initiation of high-
afﬁnity β-catenin S45 phosphorylation by CK1, which is a prerequi-
site for subsequent phosphorylation by GSK3β at S33/S37/T41,
ubiquitination, and proteasomal degradation [35–38]. Breast cancer
cells with Rad6B overexpression show elevated levels of β-catenin
unphosphorylated at S33/S37/T41. In vitro reactions examining the
impact of recombinant Rad6B on CK1α-mediated GST-β-catenin
S45 phosphorylation showed only modest inhibition. Besides S45
phosphorylation of β-catenin, N-terminal cleavage of GST-β-
catenin occurred in reactions containing CK1α (data not shown). It
is not clear at present if Rad6B inhibition of CK1α activity was com-
promised by CK1α cleavage of β-catenin.Elevated levels of Rad6B ubiquitin conjugating activity and a signiﬁ-
cant positive association between Rad6B and polyubiquitinated β-
catenin in invasive breast carcinomas support an important role for
Rad6B inβ-catenin regulation in clinical breast cancer. Rad6B canmediate
β-catenin ubiquitination in vitro in the absence of an E3 ligase. It is likely,
however, that the proﬁcient β-catenin polyubiquitination observed in
breast tumors involves E3 ligase(s). In this context it should be noted
that Rad6B silencing inMDA-MB-231 andWS-15 breast cancer cells sup-
presses β-catenin polyubiquitinationwhile sparing the nascent β-catenin
protein, indicating a major requirement for the Rad6B E2 function in this
process [9].
βTrCP ubiquitination of β-catenin K19 and K49 primes it for
proteasomal degradation [39,40], and as expected, K19/K49R dou-
ble mutant β-catenin levels are stabilized due to reduced βTrCP-
dependent ubiquitination [40]. Overexpression of a dominant neg-
ative βTrCP1 potently inhibited mono- but not polyubiquitination
of wild type, K19R-, K49R-, K19/K49R-, and S33Y-mutant β-
catenin [40]. These data imply the presence of additional ubiquitinating
mechanisms (possibly Rad6B) and ubiquitination sites besides K19 and
K49. Among the lysine residues 312, 335, 345, 354, and 394 located in
Fig. 5. K394R mutation decreases β-catenin levels and transcriptional activity. (A) TOP/Flash activities (mean±S.E.M). *Indicates signiﬁcant difference as compared to control
(Pb0.01). (B) TOP/Flash activity assays with increasing amounts (1–4 μg) of wild type or K394R-β-catenin. Lower panel, Western blot analysis of indicated proteins. (C) Rad6B
mRNA expression relative to GAPDH (mean±S.E.M) in MCF-7 cells transfected with myc-tagged wild type or mutant β-catenin vectors. *Indicates signiﬁcant difference as com-
pared to control (Pb0.01). (D). Steady-state levels of the indicated proteins in nontransfected (ﬁrst lane) or transfected with the indicated β-catenin. (E) MG132 does not affect
the steady state levels of K394R-β-catenin. Myc tag antibody immunoblots of K394R- or wild type (WT) β-catenin in MCF-7 cells with or without MG132 treatment.
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induced ubiquitination. Rad6B silencing reduced K354R- and wild
type-β-catenin ubiquitination but not K394R-β-catenin, providing fur-
ther support for a physiological role of Rad6B in K394-β-catenin
ubiquitination. Interestingly, the UbPred program [41] predicted K394
as a potential ubiquitination site with similar conﬁdence scores as K49
(score 0.67), an established ubiquitination site besides K19 (score 0.8).
Lysines 394 and 345 are surface-exposed residues [42], and like
K345, K394 may be readily accessible for modiﬁcation and/or serve as
a contact site for β-catenin partners. Lysine 345 is a major site of acety-
lation, which increases β-catenin afﬁnity for TCF4. The K345Rmutation
caused a 50% decrease in activation of TOP/Flash in HeLa cells [43].
However, in MCF-7 cells K345R mutation caused only a marginal drop
in TOP/Flash activity, potentially reﬂecting cell type differences. K394R
mutation caused an ~50% drop in TOP/Flash activity compared to wild
type β-catenin, and consistent with the TOP reporter activation data,
Rad6B expression, itself a β-catenin/TCF transcriptional target [10],
was reduced in K394R-β-catenin transfected MCF-7 cells. Our data
showed that compared to wild type and K312R, K335R, K345R and
K354R β-catenin mutants, K394R-β-catenin steady-state protein levels
were decreased in MCF-7 cells. The reduced K394R-β-catenin steady-
state protein levels were not due to 26S proteasomal degradation,
since treatment with proteasomal inhibitor MG132 failed to rescue it.
The failure of MG132 treatment to enhance K394R-β-catenin levels
suggests this additional ubiquitination does not occur at K19 and K49,as their ubiquitination is associated with proteasomal degradation.
These data suggest that K394 is a novel ubiquitination site and poten-
tially an important charge button for maintaining the overall structure
and stability of β-catenin.
c-Myc promoter-driven luciferase expression (data not shown)
and protein levels were downregulated, although not as dramatically
as Rad6B, in K394R-β-catenin transfected cells. In contrast, cyclin D1
protein and cyclin D1 promoter-mediated reporter expression [44]
were unaffected by β-catenin mutation. These data suggest that tar-
get gene cis-acting elements respond to and interact differently
with modiﬁed β-catenin to regulate gene expression.
Rad6B mutations have not been found in breast cancer [8]. The
frequent Rad6B overexpression and presence of activated β-catenin
in clinical breast cancer suggests the possibility of in vivo β-catenin
K394 ubiquitination. Rad6B, like β-catenin, is present in the cyto-
plasm and nucleus of Wnt active breast cancer cells [9], and like β-
catenin, Rad6B shuttles in and out of the nucleus. This coexistence
and ability to shuttle between the nucleus and cytoplasm could pro-
vide ample opportunity for β-catenin modiﬁcation, stabilization and
activation by Rad6B. Cytoplasmic or nuclear expression of β-catenin
is reported in ~60% of human breast cancers and is shown to indepen-
dently correlate with poor prognosis [45]. Considering the physiolog-
ical link between Rad6B and β-catenin stabilization, targeting Rad6B
may provide a novel strategy for disrupting activated canonical Wnt
signaling in breast cancers [46–48].
Fig. 6. Breast carcinomas display elevated Rad6, Rad6 ubiquitin conjugating activity, and polyubiquitinated β-catenin. (A) Steady state levels of Rad6 and β-catenin. High MW β-
catenin fraction is indicated by a bracket. (B and C) Steady-state levels of the indicated proteins in RM (reduction mammoplasty), LN− (lymph-node negative), LN+ (lymph-node
positive) and Met LN (metastatic lymph nodes). (D) Graphic representation of Rad6, nascent β-catenin, and high MW β-catenin levels. *Indicates statistical signiﬁcance. (E) In vitro
ubiquitination of histone H2A with RM, LN−, and LN+ breast tissue extracts, and detected with ubiquitin antibody. *LN+ indicates the same LN+ breast cancer sample subjected
to reactions with or without catalytically mutant (Mut) rad6B. Bottom, corresponding levels of Rad6 in the reactions. In the ﬁrst lane, positive control reaction with histone H2A and
recombinant wild type Rad6B. Arrow indicates the position of ubiquitinated histone H2A. (F) *LN+ indicates the same tissue extract sample that was subjected to ubiquitination
reactions with or without H2A (lanes 2 and 4) or following immunodepletion with normal rabbit IgG or Rad6 antibody (lanes 3 and 5). The last lane shows a positive control re-
action with H2A and recombinant Rad6B. Arrow indicates the position of ubiquitinated histone H2A. (G) Ubiquitination of histone H2A by Rad6B. (Left) Reactions with or without
Rad6B and detected by silver stain. (Right) Reactions performed with or without H2A, and detected with ubiquitin antibody.
1695B. Gerard et al. / Biochimica et Biophysica Acta 1823 (2012) 1686–16965. Conclusions
The oncogenic activity of β-catenin is rendered through its
function as a transcription factor. Breast cancer differs from most
cancers in that elevated β-catenin mediated transcriptional activi-
ty is found despite the absence of β-catenin stabilizing mutations.
The identiﬁcation of Rad6B/β-catenin physical interaction, a
Rad6B-induced ubiquitination site of β-catenin and its potentialeffect on β-catenin transcriptional activity provide a new model
for β-catenin oncogenicity in breast cancer.
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